Advocacy Groups Push ICER To Reevaluate Migraine Drug Analysis

By Ariel Cohen / February 27, 2020 at 3:25 PM
Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors. The advocacy groups expect the cost-effectiveness rating of the three drugs would increase further using that framework. On Tuesday (Feb. 25), the Institute for Clinical and Economic Review reversed direction and decided that a pair of drugs for treating migraines are more useful...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.